

BMJ Open

The prevalence of type 2 diabetes among older people in Africa: A Systematic Review Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004747
Article Type:	Protocol
Date Submitted by the Author:	23-Dec-2013
Complete List of Authors:	Werfalli, Mahmoud; Chronic Disease Initiative for Africa, Department of Medicine, Faculty of Health Science, university of Cape Town Musekiwa, Alfred; Stellenbosch University, Centre for Evidence Based Health Care Engel, Mark; University of Cape Town, Medicine Ross, Ian; University of Cape Town, Division of Diabetic Medicine and Endocrinology, Department of Medicine Kengne, Andre; South African Medical Research Council, Levitt, Naomi; University of Cape Town , medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Public health, Epidemiology, Evidence based practice, Geriatric medicine, Research methods
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, GENERAL MEDICINE (see Internal Medicine), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, STATISTICS & RESEARCH METHODS

SCHOLARONE™
Manuscripts

The prevalence of type 2 diabetes mellitus among older people in Africa: A Systematic Review Study Protocol

Correspondence to: Mahmoud Werfalli Mahmoud.werfalli@yahoo.com

Mahmoud Werfalli^{1,4}, Alfred Musekiwa², Mark Engel³ Ian Ross⁴, Andre P Kengne^{2,5} and Naomi S Levitt^{1,4}

Chronic Disease Initiative for Africa (CDIA),¹ Centre for Evidence Based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa² Department of Medicine, University of Cape Town, Cape Town, South Africa³, Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa⁴ Non-Communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, South Africa⁵

Key words : elderly, diabetes mellitus, type 2 diabetes, prevalence, Africa

Abstract

Introduction: The number of people with diabetes in Africa is projected to increase substantially in the next two decades, explained by a number of factors. These include rapid urbanization, adoption of unhealthy diets and exercise patterns, and the ageing of the population. There are currently uncertainties regarding the incidence, prevalence, and management patterns of diabetes in older people across the diversity of African countries. We wish to perform a systematic review to determine the prevalence of type 2 diabetes in Africa in the older individual, over the age of 55 years, reported in studies from 2000 to 2013, hypothesising that it may be higher than reported in Western countries.

Methods and analyses: A comprehensive literature search will be undertaken, using an African search filter to identify diabetes prevalence studies that were published from 2000 to 2013. The African filter comprises African country names as well as truncated terms such as 'north* Africa' to ensure that records indexed using regional terms rather than country-specific terms are also captured. Database subject headings (MeSH in PUBMED /MEDLINE, CINHALL, scholarly Google) will be combined with a range of text words (African search filter). Publications of identified key authors will be examined by citation searches on MEDLINE and (ISI) Web of Science. The World Health Organization (WHO) and International Diabetes Federation (IDF) websites will be searched. Full copies of articles identified by the search, and considered to meet the inclusion criteria, will be obtained for data extraction and synthesis. Two reviewers will apply the criteria independently to the

1
2
3 results; prevalence of type 2 diabetes from different studies will be pooled in a meta-analysis using
4 (STATA version 12 statistical software). This systematic review will be reported according to the
5 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).
6
7
8
9

10 **Introduction**

11
12 During the last decade the prevalence of type 2 diabetes has increased dramatically in many parts of
13 the world. The International Diabetes Federation (IDF) projects an increase in the number of people
14 living with diabetes from 382 million in 2013 to 592 million by 2035, should there be no serious
15 action to stem this tide.¹ In Africa, diabetes already contributes significantly to morbidity and
16 mortality with the highest global age-specific mortality rate recorded in this part of the world.²⁻⁵ As
17 such a broad based strategy aimed at prevention, early identification and appropriate management is
18 critical to reduce the burden of diabetes in Africa.⁵
19
20
21
22
23

24 The annual growth rate of older persons in Africa has been estimated at 3.1% between 2007 and
25 2015, and 3.3% between 2015 and 2050, which is greater than the global average.² Given that aging is
26 one of the major drivers for diabetes, it is concerning that there will be approximately 64.5 million
27 African persons aged ≥ 55 years in 2015, and more than 103 million and 205 million in 2030 and
28 2050, respectively.⁶ Delivering appropriate care for older people with diabetes presents a growing
29 challenge to all health-care systems. Health literacy, comorbidities, polypharmacy, higher risk of
30 cognitive impairment, functional limitations, and financial problems significantly affect the ability of
31 older people in general to understand and follow complex treatment regimens.⁷ Yet guidelines for the
32 older person with diabetes are limited by a dearth of evidence and therefore recommendations rely on
33 expert opinion and extrapolation from younger populations.⁸ Diabetes, in view of its high prevalence,
34 prolonged duration, wide spectrum of complications, emotional and psychological sequelae, provides
35 a complex case for cost-effective studies, in older people.⁹
36
37
38
39
40
41
42
43

44 **Why it is important to do this review**

45
46 In view of the anticipated growth of older people with diabetes globally and in Africa in particular,
47 adequate baseline epidemiological data are required to monitor future trends. We therefore wish to
48 perform a systematic review to determine the prevalence of type 2 diabetes in Africa in older
49 individuals over the age of 55 years, reported in studies from 2000 to 2013, hypothesising that it may
50 be higher than reported in Western countries.
51
52
53
54
55
56
57
58
59
60

Objectives

To conduct a systematic review of studies assessing the prevalence of Type 2 diabetes among older people in African countries.

Review question

This systematic review will be guided by the following research question:

What is the prevalence of type 2 diabetes in older persons aged 55 years and older in African countries as reported in studies from 2000 to 2013?

Criteria for considering studies for review

We will consider published articles and unpublished studies reported after 01 January 2000, given that the current criteria for the diagnosis of diabetes have been widely accepted since 1998. Articles published in English or in other languages, with full English abstracts will be eligible for inclusion.

Types of participants

Participants aged 55 years or older, resident in countries belonging to the African continent, in the geographic regions of Sub-Saharan Africa and North Africa diagnosed with type 2 diabetes from all ethnicities, socioeconomic and educational backgrounds will be eligible for inclusion. For the purpose of this review, the diagnosis of diabetes can either be made by physician or defined by available measured fasting plasma glucose (FPG), glucose tolerance test (OGTT) or self-reported, according to WHO criteria.¹⁰

Types of studies

Population-based studies, cross-sectional studies such as (cross-sectional survey) of type 2 diabetes defined by the WHO, will be potentially eligible for inclusion.

Exclusion criteria

1. Studies confined to subgroups of patients with type 2 diabetes (with any complication of diabetes mellitus for example: myocardial infarction, eye, kidney or other microvascular or macrovascular complications).
2. Studies that do not include a representative sample of older people aged 55 years or older.
3. Narrative reviews, opinion pieces, letters, or any other publications lacking primary clinical data and/or explicit methods descriptions.

- 1
2
3 4. Duplicate publications of the same material. When the study has been published in more than
4 one journal/conference, the most complete recent version will be used.
5
6
7

8 **Search strategy for identification of relevant studies**

9
10
11 The search strategy will be designed to access both published and unpublished studies and will
12 comprise two stages:
13

14 **Bibliographic databases**

- 15
16
17
18
19 A. A comprehensive and sensitive search strategy will be undertaken using a comprehensive
20 African search filter developed by Siegfried ¹¹ to identify prevalence studies conducted from
21 2000 to 2013 in Africa. The African filter comprises African country names as well as
22 truncated terms such as ‘north* Africa’ to ensure that records indexed using regional terms
23 rather than country-specific terms are also retrieved. Database subject headings (MeSH in
24 PUBMED/MEDLINE, CINHALL and scholarly Google) will be combined with a range of text
25 words (See Appendix 1). African country names are included in both English and languages
26 relevant to the country, e.g., ‘Ivory Coast’ and ‘Cote d’Ivoire’. Where country names have
27 changed over time both names are included, e.g., ‘Democratic Republic of Congo ’and
28 ‘Zaire’.¹²
29
30
31
32
33
34
35
36 B. Publications of identified key authors will be examined by citation searches on the websites
37 of the IDF and WHO e.g. STEPS surveys studies in Africa as well as ‘free word’ Internet
38 searches on ISI Web of Science. No language restrictions will be used, Bibliographic software
39 programs for managing the references and documenting the study selection process (Ref
40 Works) will be used in this review. An expert librarian will help in designing the search
41 strategy framework and implementing the appropriate bibliographic software program. For
42 the detailed search strategy (See Appendix 2).
43
44
45
46
47

48 **Selecting studies for inclusion**

49
50
51 Full copies of articles identified by the search, and considered to meet the inclusion criteria, based
52 on the title and abstract will be obtained for data synthesis. Initially, studies will be screened using
53 pre-defined inclusion and exclusion criteria. Two reviewers will apply the criteria independently
54 to the results of the searches, based first on titles and abstracts only. Studies will then be either
55 (A) excluded, (B) included, or (C) marked as “Pending” if the reviewer is unsure about their
56
57
58
59
60

inclusion. The two independent reviews will be compared and contradictory judgments or “pending” will be temporarily “included”, and moved to the next phase of review of full texts. Once full texts have been retrieved, two reviewers will independently apply inclusion and exclusion criteria, based on quick assessments of the full texts. Disagreements in reviewer selections will be resolved at a meeting between reviewers prior to selected articles being retrieved. A flow chart will be produced to facilitate transparency of the process.

Quality appraisal of included studies

In this review, methodological quality will be distanced from general reporting quality as it is important to clarify and differentiate between quality of reporting and the quality of what was actually done (that is, a study could be well reported but have methodological limits or vice versa). Sensitivity analyses will be based on stratification, by individual items of methodological quality or (where appropriate) individual items of general reporting quality to assess the robustness of the findings. The Guidelines for Evaluating Prevalence Studies developed by Hoy¹³ will be used. These guidelines measure the quality of studies across two main areas: both external and internal validity (**Table 1**).

Table 1. Quality assessment criteria for Prevalence studies¹³

External validity	
1. Was the study’s target population a close representation of the national population in relation to relevant variables? (1 point)	
2. Was the sampling frame a true or close representation of the target population? (1 point)	
3. Was some form of random selection used to select the sample, OR was a census undertaken? (1 point)	
4. Was the likelihood of nonresponse bias minimal? (1 point)	
	Total points (4 points)
Internal validity	
1. Were data collected directly from the subjects (as opposed to a proxy)? (1 point)	
2. Was an acceptable case definition used in the study? (1 point)	
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability? (1 point)	
4. Was the same mode of data collection used for all subjects? (1 point)	
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point)	
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point)	
	Total points (6 points)

Data extraction and management

Following assessment of methodological quality, two reviewers will extract data onto a purpose-designed data extraction form and independently summarize what they consider to be the most important results from each study. These summaries will be compared and any differences of opinion will be resolved by discussion and consultation with a third reviewer. Any further calculations on study data considered necessary, will be conducted by the first reviewer and checked by the second reviewer. Study characteristics including country where study was conducted, year of publication, journal, language of publication, study population, age range, response rate, study design, criteria for sample selection and sample size, outcome(s) measured, diagnostic criteria, results and notes/comments will be presented in Tables (See Appendix 3). We are anticipating that some eligible studies will not have prevalence data reported for the specific age range (i.e. ≥ 55 years). We will contact the corresponding authors of these studies and request the age-specific prevalence and any other missing information, deemed to be relevant.

Data synthesis including assessment of heterogeneity

Our analysis of the primary measure, FPG and OGTT will include two steps: (1) identification of data sources and documenting estimates and (2) application of statistical models, to estimate the prevalence by country and age. Prevalence of type 2 DM from different studies will be pooled in a meta-analysis using (STATA version 12 statistical software). Heterogeneity between combined studies will be tested using the I^2 heterogeneity statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. Heterogeneity will be assessed by inspecting forest plots initially, then through the Cochran's Chi-square test (using 10% level of significance due to the low power of the test), and the I-square statistic (where 50% or higher values indicate substantial heterogeneity).¹⁴ Where heterogeneity is statistically significant, subgroup analysis and sensitivity analyses will be conducted to determine the potential sources of heterogeneity. If the identified studies are of substantial heterogeneity and where statistical pooling is not possible, the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. The narrative will be written by the two reviewers and then checked independently by the other reviewers, any disagreements will be decided by all reviewers.

Assessment of reporting biases

Symmetry of funnel plots will be used to assess for publication or selective reporting bias.

Reporting of this review

This systematic review will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement.¹⁵ A reporting guideline for systematic reviews of healthcare intervention and will include a PRISMA checklist. Where necessary, we will adapt the reporting to ensure that all items relevant to this review are included in the report.

Ethics and Dissemination

This study will attempt to fill the gap in knowledge in the prevalence of diabetes among the older population in Africa. As such it will provide impetus to develop an evidence base for policy and practice in this area of research. The study will be disseminated by peer-review publication and conference presentations.

Acknowledgements: We acknowledge Dr Taryn Young, Evidence-based health care Centre, and University of Stellenbosch, who provided guidance for designing the protocol. Ms Tamzyn Suliaman, UCT Libraries, Health Sciences, Information Services Librarian who provided, technical support and assists in the planning of the search strategy and reference management.

Contributors: All authors conceived the study and were responsible for designing the protocol. M. Werfalli and A Musekiwa codrafted the protocol manuscript and NS Levitt and ME. Engel, I. Ross, A. Kengne revised it for methodological and clinical content. All authors critically revised successive drafts of the manuscripts and approved the final version.

Funding: None

Competing interests: None declared.

References

- 1- Leonor G. "Contribute data to the 6th edition of the IDF Diabetes Atlas." *Diabetes Res Clin Pract.* 100.2 (2013): 280-281.
- 2- Alli F, Maharaj P. The Health Situation of Older People in Africa. *Aging and Health in Africa* Springer; 2013. p. 53-89.
- 3- Steyn K, Damasceno A. Lifestyle and related risk factors for chronic diseases. *Disease and mortality in sub-Saharan Africa.* 2006; 2.
- 4- Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. *Diabetes Res Clin Pract* 2011; 94(3):322-3
- 5- Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart* 2008; 94(11):1376-82.
- 6- Naidoo N, Abdullah S, Bawah A, Binka F, Chuc NT, Debpuur C, et al. Ageing and adult health status in eight lower-income countries: the INDEPTH WHO-SAGE collaboration. *Global Health Action* 2010:11
- 7- Sue Kirkman M, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. *J Am Geriatr Soc* 2012; 60(12):2342-56.
- 8- Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. *Oman Medical Journal* 2012; 27(4):269.
- 9- Varghese R. A clinical study of diabetes mellitus in elderly, with special emphasis on its complications 2012.
- 10- World Health Organization, World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. *Geneva: World Health Organization* 2006:1-50.
- 11- Eisinga A, Siegfried N, Clarke M. The sensitivity and precision of search terms in Phases I, II and III of the Cochrane Highly Sensitive Search Strategy for identifying reports of randomized trials in Medline in a specific area of health care—HIV/AIDS prevention and treatment interventions. *Health Information & Libraries Journal* 2007; 24(2):103-9.
- 12- Pienaar E, Grobler L, Busgeeth K, Eisinga A, Siegfried N. Developing a geographic search filter to identify randomised controlled trials in Africa: finding the optimal balance between sensitivity and precision. *Health Information & Libraries Journal* 2011; 28(3):210-5.
- 13- Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 2012.
- 14- Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of interventions.* Wiley Online Library; 2008.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

15- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009; 151(4):264-9.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-004747 on 17 June 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Article summary

Article focus

- This systematic review aims to fill the gap in knowledge in the prevalence of diabetes among older population in Africa.

Key messages

- There are currently important gaps in our knowledge on the incidence and prevalence of diabetes mellitus and management patterns for older people in Africa, setting priorities in service delivery for the prevention and treatment of type 2 diabetes requires an empirical understanding of the pattern of disease burden

Strengths and limitations of this study

- A comprehensive search strategy will be undertaken using African search filter to identify prevalence Studies conducted from 2000 to 2013 in Africa.
- There is a lack of qualitative and quantitative research on the health status of the older population.
- Sensitivity analyses will be based on stratification by individual items of methodological quality.

Appendix 2: Describing details of search strategy

A. Describing the relevant search terms used in search strategy.

elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]
people	"persons"[MeSH Terms] OR "persons"[All Fields] OR "people"[All Fields]
diabetes mellitus	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields]
type 2 diabetes	"diabetes mellitus, type 2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]
Africa	"Africa"[MeSH Terms] OR "Africa"[All Fields]
diabetes	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR "diabetes"[All Fields] OR "diabetes insipidus"[MeSH Terms] OR ("diabetes"[All Fields] AND "insipidus"[All Fields]) OR "diabetes insipidus"[All Fields]
prevalence	"epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms]

B. Describing electronic databases searches by using of African Search Filter

(elderly)) AND (elderly people)) AND (diabetes mellitus)) AND (2 diabetes mellitus)) AND (type 2 diabetes)) AND (Africa)) AND (("Africa"[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR "Burkina Faso"[tw] OR Burundi[tw] OR Cameroon[tw] OR "Canary Islands"[tw] OR "Cape Verde"[tw] OR "Central African Republic"[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR "Democratic Republic of Congo"[tw] OR Djibouti[tw] OR Egypt[tw] OR "Equatorial Guinea"[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR "Guinea Bissau"[tw] OR "Ivory Coast"[tw] OR "Cote d'Ivoire"[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR "Sao Tome"[tw] OR Senegal[tw] OR Seychelles[tw] OR "Sierra Leone"[tw] OR Somalia[tw] OR "South Africa"[tw] OR "St Helena"[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR "Western Sahara"[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR "Central Africa"[tw] OR "Central African"[tw] OR "West Africa"[tw] OR "West African"[tw] OR "Western Africa"[tw] OR "Western African"[tw] OR "East Africa"[tw] OR "East African"[tw] OR "Eastern Africa"[tw] OR "Eastern African"[tw] OR "North Africa"[tw] OR "North African"[tw] OR "Northern Africa"[tw] OR "Northern African"[tw] OR "South African"[tw] OR "Southern Africa"[tw] OR "Southern African"[tw] OR "sub Saharan Africa"[tw] OR "sub Saharan African"[tw] OR "sub-Saharan Africa"[tw] OR "sub-Saharan African"[tw]) NOT ("guinea pig"[tw] OR "guinea pigs"[tw] OR 'aspergillums Niger'[tw])) AND (diabetes prevalence) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms])

APPENDIX 3: DATA EXTRACTION FORM

STUDY ID:

Reviewer's Initials

Part 1: COVERSHEET

Study Title:

Journal:

Language:

Citation:

Part 2: STUDY CHARACTERISTICS.

Publication Year:

Country of study:

Study design:

- cross-sectional
- case-report
- other _____

Study period:

Data source:

- medical records
- special survey
- multiple source
- surveillance
- registries

Setting

- Urban
- Rural

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p><u>Population study:</u></p> <p><input type="checkbox"/> total population</p> <p><input type="checkbox"/> specific group population</p> <p><input type="checkbox"/> other _____</p> <p><u>Diagnostic Criteria.</u></p> <ul style="list-style-type: none"> ❖ WHO Criteria: (Y / N). ❖ Measured or Defined by: <ul style="list-style-type: none"> • Fasting plasma glucose (FPG) <input type="checkbox"/> • glucose tolerance test (OGT) <input type="checkbox"/> • Self-reported <input type="checkbox"/> <p>❖ Please use the attached checklist (Tick as appropriate (✓))</p> <p>Inclusion criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Exclusion Criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Included <input type="checkbox"/> Excluded <input type="checkbox"/> pending <input type="checkbox"/></p>	<p><u>Age groups included (describe):</u></p> <div style="border: 1px solid black; height: 40px; margin-bottom: 10px;"></div> <p><u>Genders included:</u> (Total numbers)</p> <p>Male <input type="checkbox"/></p> <p>Female <input type="checkbox"/> <div style="border: 1px solid black; width: 100px; height: 20px; display: inline-block; vertical-align: middle;"></div></p> <p>Both <input type="checkbox"/> <div style="border: 1px solid black; width: 100px; height: 20px; display: inline-block; vertical-align: middle;"></div></p> <p><u>Dominator (s) (N):</u> <div style="border: 1px solid black; width: 100px; height: 20px; display: inline-block; vertical-align: middle;"></div></p> <hr/> <p>Reason(s) for exclusion, uncertainty or to contact authors</p> <div style="border: 1px solid black; padding: 5px; min-height: 100px;"> <p>1.</p> <p>2.</p> <p>3.</p> </div>
--	---

Part 3: RESULTS.

Measure of the prevalence

Crude Measure

Adjusted measure

If **adjusted** what factors were adjusted for in this study (list):

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reported measure of the prevalence:

Missing data to be reported from the author:

(any communication with author Yes No

If yes, please specify

Other comments:

Peer review only

Appendix 1: African Search Filter

African Search Filter

(“Africa”[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR “Burkina Faso”[tw] OR Burundi[tw] OR Cameroon[tw] OR “Canary Islands”[tw] OR “Cape Verde”[tw] OR “Central African Republic”[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR “Democratic Republic of Congo”[tw] OR Djibouti[tw] OR Egypt[tw] OR “Equatorial Guinea”[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR “Guinea Bissau”[tw] OR “Ivory Coast”[tw] OR “Cote d’Ivoire”[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR “Sao Tome”[tw] OR Senegal[tw] OR Seychelles[tw] OR “Sierra Leone”[tw] OR Somalia[tw] OR “South Africa”[tw] OR “St Helena”[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR “Western Sahara”[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR “Central Africa”[tw] OR “Central African”[tw] OR “West Africa”[tw] OR “West African”[tw] OR “Western Africa”[tw] OR “Western African”[tw] OR “East Africa”[tw] OR “East African”[tw] OR “Eastern Africa”[tw] OR “Eastern African”[tw] OR “North Africa”[tw] OR “North African”[tw] OR “Northern Africa”[tw] OR “Northern African”[tw] OR “South African”[tw] OR “Southern Africa”[tw] OR “Southern African”[tw] OR “sub Saharan Africa”[tw] OR “sub Saharan African”[tw] OR “sub-Saharan Africa”[tw] OR “sub-Saharan African”[tw]) NOT (“guinea pig”[tw] OR “guinea pigs”[tw] OR ‘aspergillums Niger”[tw])

Appendix 2: Describing details of search strategy

A. Describing the relevant search terms used in search strategy.

elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]
people	"persons"[MeSH Terms] OR "persons"[All Fields] OR "people"[All Fields]
diabetes mellitus	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields]
type 2 diabetes	"diabetes mellitus, type 2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]
Africa	"Africa"[MeSH Terms] OR "Africa"[All Fields]
diabetes	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR "diabetes"[All Fields] OR "diabetes insipidus"[MeSH Terms] OR ("diabetes"[All Fields] AND "insipidus"[All Fields]) OR "diabetes insipidus"[All Fields]
prevalence	"epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms]

B. Describing electronic databases searches by using of African Search Filter

(elderly)) AND (elderly people)) AND (diabetes mellitus)) AND (2 diabetes mellitus)) AND (type 2 diabetes)) AND (Africa)) AND (("Africa"[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR "Burkina Faso"[tw] OR Burundi[tw] OR Cameroon[tw] OR "Canary Islands"[tw] OR "Cape Verde"[tw] OR "Central African Republic"[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR "Democratic Republic of Congo"[tw] OR Djibouti[tw] OR Egypt[tw] OR "Equatorial Guinea"[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR "Guinea Bissau"[tw] OR "Ivory Coast"[tw] OR "Cote d'Ivoire"[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR "Sao Tome"[tw] OR Senegal[tw] OR Seychelles[tw] OR "Sierra Leone"[tw] OR Somalia[tw] OR "South Africa"[tw] OR "St Helena"[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR "Western Sahara"[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR "Central Africa"[tw] OR "Central African"[tw] OR "West Africa"[tw] OR "West African"[tw] OR "Western Africa"[tw] OR "Western African"[tw] OR "East Africa"[tw] OR "East African"[tw] OR "Eastern Africa"[tw] OR "Eastern African"[tw] OR "North Africa"[tw] OR "North African"[tw] OR "Northern Africa"[tw] OR "Northern African"[tw] OR "South African"[tw] OR "Southern Africa"[tw] OR "Southern African"[tw] OR "sub Saharan Africa"[tw] OR "sub Saharan African"[tw] OR "sub-Saharan Africa"[tw] OR "sub-Saharan African"[tw]) NOT ("guinea pig"[tw] OR "guinea pigs"[tw] OR 'aspergillums Niger'[tw])) AND (diabetes prevalence) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms])

APPENDIX 3: DATA EXTRACTION FORM

STUDY ID:

Reviewer's Initials

Part 1: COVERSHEET

Study Title:

Journal:

Language:

Citation:

Part 2: STUDY CHARACTERISTICS.

Publication Year:

Country of study:

Study design:

- cross-sectional
- case-report
- other _____

Study period:

Population study:

- total population
- specific group population
- other _____

Diagnostic Criteria.

- ❖ WHO Criteria: (Y / N).
- ❖ Measured or Defined by:
 - Fasting plasma glucose (FPG)
 - glucose tolerance test (OGT)
 - Self-reported

Data source:

- medical records
- special survey
- multiple source
- surveillance
- registries

Setting

- Urban
- Rural

Age groups included (describe):

Genders included:

(Total numbers)

- Male
- Female
- Both

Dominator (s) (N):

<p>❖ Please use the attached checklist (Tick as appropriate (√))</p> <p>Inclusion criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Exclusion Criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Included <input type="checkbox"/> Excluded <input type="checkbox"/> pending <input type="checkbox"/></p>	<p>Reason(s) for exclusion, uncertainty or to contact authors</p> <div style="border: 1px solid black; padding: 5px; min-height: 80px;"> <p>1.</p> <p>2.</p> <p>3.</p> </div>
--	--

Part 3: RESULTS.

Measure of the prevalence

Crude Measure

Adjusted measure

If **adjusted** what factors were adjusted for in this study (list):

Reported measure of the prevalence:

Missing data to be reported from the author:
 (any communication with author Yes No
If yes, please specify


Other comments:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open: first published as 10.1136/bmjopen-2013-004747 on 17 June 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

BMJ Open

The prevalence of type 2 diabetes among older people in Africa: A Systematic Review Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004747.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Apr-2014
Complete List of Authors:	Werfalli, Mahmoud; Chronic Disease Initiative for Africa, Department of Medicine, Faculty of Health Science, university of Cape Town Musekiwa, Alfred; Stellenbosch University, Centre for Evidence Based Health Care Engel, Mark; University of Cape Town, Medicine Ross, Ian; University of Cape Town, Division of Diabetic Medicine and Endocrinology, Department of Medicine Kengne, Andre; South African Medical Research Council, Levitt, Naomi; University of Cape Town , medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts

Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The prevalence of type 2 diabetes mellitus among older people in Africa: A Systematic Review Study Protocol

Correspondence to: Naomi Levitt Naomi.levitt@uct.ac.za

Mahmoud Werfalli^{1,3,4}, Alfred Musekiwa², Mark E, Engel Ian Ross,^{3,4} Andre P Kengne^{2,5} and Naomi S Levitt^{1,3,4}

Chronic Disease Initiative for Africa (CDIA),¹ Centre for Evidence Based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa² Department of Medicine, University of Cape Town, Cape Town, South Africa³, Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa⁴ Non-Communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, South Africa⁵

Key words: elderly, diabetes mellitus, type 2 diabetes, prevalence, Africa

Abstract

Introduction: The number of people with diabetes in Africa is projected to increase substantially in the next two decades, due to factors including rapid urbanization, adoption of unhealthy diets and exercise patterns, and the ageing of the population. There are currently uncertainties regarding the incidence, prevalence, and management patterns of diabetes in older people across the diversity of African countries. We wish to perform a systematic review to determine the prevalence of type 2 diabetes in Africa in the older individual, over the age of 55 years, reported in studies from 2000 to 2013.

Methods and analyses: A comprehensive literature search among a number of databases will be undertaken, using an African search filter to identify diabetes prevalence studies that were published from 2000 to 2013. Full copies of articles identified by the search, and considered to meet the inclusion criteria, will be obtained for data extraction and synthesis. Statistical analysis of the primary measures, fasting plasma glucose (FPG) and glucose tolerance test (OGTT) will include two steps: (1) identification of data sources and documenting estimates and (2), application of the random-effects meta-analysis model to aggregate prevalence estimates and account for between study variability in calculating the overall pooled estimates and 95% confidence interval (CI) for diabetes prevalence. Heterogeneity will be evaluated using the I-square statistic (I²) to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. This systematic review will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).

Ethics and dissemination: Ethics is not required for this study, given that this is a protocol for a systematic review, which utilizes published data. The findings of this study will be widely disseminated through peer-reviewed publications and conference presentations.

Introduction

The most recent International Diabetes Federation estimates from 2013 are that 8.3% of adults i.e. 382 million people world-wide have diabetes. This number has doubled over the past 20 years, and notably 80% of people with diabetes live in low and middle income countries (LMIC).¹ Diabetes

1
2
3 already contributes significantly to morbidity and mortality in Africa. The highest global age-specific
4 mortality rate is recorded in this continent. ²⁻⁶All countries in Africa fall all into the LMIC category,
5 and predominantly the low income category, The rise in the number of people with type 2 diabetes in
6 Africa, similar to LMIC s been attributed to ageing of the population and relatively rapidly changing
7 environmental factors.¹ These include urbanisation, the adoption of health behaviours favouring
8 sedentariness and unhealthy eating patterns. While unhealthy behaviour patterns and obesity are
9 potentially modifiable, ageing one of the major drivers for diabetes, is not.⁷ In 2013, the majority of
10 individuals with diabetes in Africa were reported to be under than 60 years of age with the highest
11 proportion (43.2%) in people aged 40–59 years.⁷ The relatively small proportion of people aged 60–
12 79 years of age in the region is likely to account for the estimate that only 18.8% of people with
13 diabetes fall in this age group.¹
14
15
16
17
18
19

20
21 Africa is often referred to as the youngest continent in terms of age structure. This may contribute to
22 the current relatively low prioritisation of ageing issues in national policies.⁸ Yet thee annual growth
23 rate of older persons in Africa has been estimated at 3.1% between 2007 and 2015, and 3.3% between
24 2015 and 2050, greater than the global average. In this context , it is concerning that there will be
25 approximately 64.5 million African persons aged ≥ 55 years in 2015, and more than 103 million and
26 205 million in 2030 and 2050, respectively.⁶ Indeed it has been predicted that the diabetes peak in
27 Africa is expected to be in the oldest individual by 2035.¹We therefore wish to perform a systematic
28 review to determine the prevalence of type 2 diabetes in Africa in older individuals over the age of 55
29 years, reported in studies from 2000 to 2013 with a view to providing accurate data for monitoring
30 future trends. The data will also be of value in informing health policy makers of the extent of the
31 burden of diabetes in an under researched group whose health care needs may differ from those in
32 younger adult
33
34
35
36
37
38
39

40 Objectives

41
42
43
44 To conduct a systematic review and meta-analysis of studies assessing the prevalence of Type 2
45 diabetes among older people in African countries.
46
47

48 Review question

49 This systematic review will be guided by the following research question:

50
51 What is the prevalence of type 2 diabetes in older persons aged 55 years and older in African
52 countries as reported in studies from 2000 to 2013?
53
54

55 Criteria for considering studies for review

56
57
58
59
60

Inclusion criteria:

1. Studies describing the prevalence of type 2 diabetes among older adults, resident in countries belonging to the African continent, in the geographic regions of both Sub-Saharan and North Africa diagnosed with type 2 diabetes from all ethnicities, socioeconomic and educational backgrounds. Participants should be described as older adults or a minimum of 70% of participants should be within the age groups of 55-64 years, 65-74 years, or 75+ years).
2. Population-based studies, cross-sectional studies of type 2 diabetes. For the purpose of this review, the diagnosis of diabetes should be made by a physician or defined by available measured fasting plasma glucose (FPG), glucose tolerance test (OGTT) or self-reported, according to WHO criteria.⁹

We will consider published articles and unpublished studies reported after 01 January 2000, given that the current criteria for the diagnosis of diabetes have been widely accepted since 1998. Articles published in any language, with full English abstracts will be eligible for inclusion.

Exclusion criteria

1. Studies which include a mixed group of Type 1 and Type 2 participants, or that do not clearly define the type of diabetes as being Type 2, will be excluded.
2. Studies confined to subgroups of patients with type 2 diabetes (with any complication of diabetes mellitus for example: myocardial infarction, eye, kidney or other microvascular or macrovascular complications).
3. Studies that do not include a representative sample of older people aged 55 years or older.
4. Narrative reviews, opinion pieces, letters, or any other publications lacking primary data and/or explicit methods descriptions.
5. Duplicate publications of the same material. When the study has been published in more than one journal/conference, the most complete recent version will be used.
6. They had a low quality scores (equal to or below 5) in the assessment of risk of bias.

Search strategy for identification of relevant studies

The search strategy will comprise two stages:

Bibliographic databases

- 1
2
3 A. A comprehensive and sensitive search strategy will be undertaken using a African search
4 filter developed by Siegfried¹⁰ to identify prevalence studies conducted from 2000 to The
5 African filter comprises country names from the continent as well as truncated terms such as
6 ‘north* Africa’ to ensure that records indexed using regional, rather than country-specific
7 terms are also retrieved. Database subject headings (MeSH in PUBMED /MEDLINE,
8 CINHAL and Google Scholar) will be combined with a range of text words (See Appendix
9 1). African country names are included in both English and languages relevant to the country,
10 e.g., ‘Ivory Coast’ and ‘Cote d’Ivoire’. Where country names have changed over time both
11 names are included, e.g., ‘Democratic Republic of Congo ’and ‘Zaire’.¹¹
12
13
14
15
16
17
18 B. Publications of identified key authors will be examined by citation searches on the IDF and
19 WHO websites e.g. STEPS surveys studies in Africa as well as on the ISI Web of knowledge
20 platform. A bibliographic software programme for managing the references and documenting
21 the study selection process will be used for this review. An expert librarian will help in
22 designing the search strategy framework and implementing the appropriate bibliographic
23 software program. (For the detailed search strategy, see Appendix 2).
24
25
26
27
28

29 **Selecting studies for inclusion**

30
31
32 Full copies of articles identified by the search, and considered to meet the inclusion criteria, based
33 on the title and abstract will be obtained for data synthesis. Initially, studies will be screened using
34 pre-defined inclusion and exclusion criteria. Two reviewers will apply the criteria independently
35 to the results of the searches, based first on titles and abstracts only. Studies will then be either
36 (A) excluded, (B) included, or (C) marked as “Pending” if the reviewer is unsure about their
37 inclusion. The two independent reviews will be compared and contradictory judgments or
38 “pending” will be temporarily “included”, and moved to the next phase of review of full texts.
39 Once full texts have been retrieved, two reviewers will independently apply inclusion and
40 exclusion criteria, based on quick assessments of the full texts. Disagreements in reviewer
41 selections will be resolved at a meeting between reviewers prior to selected articles being
42 retrieved. A flow chart will be produced to facilitate transparency of the process.
43
44
45
46
47
48
49

50 **Quality appraisal of included studies**

51
52
53 A quality assessment tool, based on guidelines for evaluating prevalence studies as suggested by
54 Hoy¹² and colleagues has been developed (Table 1). This will be applied to screened full-text
55 articles in order to code eligibility decisions and to assess study quality and agreement between
56 investigators. Assessment of bias is built into the quality scoring scale. We plan to evaluate risk
57
58
59
60

of selection and attrition bias using the Cochrane guidelines as set out in Review Manager Version 5.2 (<http://ims.cochrane.org/RevMan>). This will inform the feasibility of and selection of studies for a pooled analysis. Any disagreements will be resolved by discussion and consensus in consultation with the third author to resolve persistent inconsistencies.

Table 1. Quality assessment criteria for Prevalence studies¹²

Items	Quality score
External validity	
1. Was the study's target population a close representation of the national population in relation to relevant variables?	(1 point)
2. Was the sampling frame a true or close representation of the target population?	(1 point)
3. Was some form of random selection used to select the sample, OR was a census undertaken?	(1 point)
4. Was the likelihood of nonresponse bias minimal?	(1 point)
	Total (4 points)
Internal validity	
1. Were data collected directly from the subjects (as opposed to a proxy)?	(1 point)
2. Was an acceptable case definition used in the study?	(1 point)
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability?	(1 point)
4. Was the same mode of data collection used for all subjects? (1 point)	(1 point)
5. Was the length of the shortest prevalence period for the parameter of interest appropriate?	(1 point)
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate?	(1 point)
	Total (6 points)

Data extraction and management

Following assessment of methodological quality, two reviewers will extract data onto a purpose-designed data extraction form and independently summarize what they consider to be the most

1
2
3 important results from each study. These summaries will be compared and any differences of opinion
4 will be resolved by discussion and consultation with a third reviewer. Any further calculations on
5 study data considered necessary, will be conducted by the first reviewer and checked by the second
6 reviewer. Study characteristics including country where study was conducted, year of publication,
7 journal, language of publication, study population, age range, response rate, study design, criteria for
8 sample selection and sample size, outcome(s) measured, diagnostic criteria, results and
9 notes/comments will be presented in Tables (See Appendix 3). We are anticipating that some eligible
10 studies will not have prevalence data reported for the specific age range (i.e. ≥ 55 years). We will
11 contact the corresponding authors of these studies and request the age-specific prevalence and any
12 other missing information, deemed to be relevant.
13
14
15
16
17
18
19

20 **Data synthesis including assessment of heterogeneity**

21 Our statistical analysis of the primary measures, FPG and OGTT will include two steps: (1)
22 identification of data sources and documenting estimates and (2), application of the random-effects
23 meta-analysis model to aggregate prevalence estimates and account for between study variability in
24 calculating the overall pooled estimates and 95% confidence interval (CI) for diabetes prevalence. We
25 will derive standard errors where studies have provided the corresponding numerator and denominator
26 for diabetes prevalence estimates. We will consider non overlapping CIs as an indication of
27 statistically significant differences. Prevalence of type 2 DM from different studies will be pooled in a
28 meta-analysis using (STATA version 12 statistical software). Heterogeneity will be assessed by
29 inspecting forest plots initially, then through the Cochran's Chi-square test using a 10% level of
30 significance cut-off. due to the low power of the test), and the I-square statistic (I²) where values of
31 25%, 50%, and 75% reflect low, medium, and high heterogeneity, respectively.¹³ Where heterogeneity
32 is statistically significant, subgroup analysis, using the following variables: age group, sex, setting e.g.
33 urban/ rural geographical region e.g., northern/ southern, Western/ Eastern, as well as sensitivity
34 analyses will be conducted to determine the potential sources of heterogeneity.
35
36
37
38
39
40
41
42
43

44 Furthermore a sensitivity analysis will be performed to evaluate how excluding studies that did not
45 meet each quality criterion would affect our overall estimate. Another sensitivity analysis will be
46 conducted to find out how our results would change if only high-quality studies were considered. If
47 the identified studies are of substantial heterogeneity and where statistical pooling is not possible, the
48 findings will be presented in narrative form including tables and figures to aid in data presentation
49 where appropriate. The narrative will be written by the two reviewers and then checked independently
50 by the other reviewers, any disagreements will be decided by all reviewers.
51
52
53
54

55 **Assessment of reporting biases**

56
57
58
59
60

Symmetry of funnel plots will be used to assess for publication or selective reporting bias.

Reporting of this review

This systematic review will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement.¹⁴ A reporting guideline for systematic reviews of healthcare intervention and will include a PRISMA checklist. Where necessary, we will adapt the reporting to ensure that all items relevant to this review are included in the report.

Ethics and Dissemination

Given that this is a protocol for a systematic review, which utilizes published data, ethics is not required for this study. The findings of this study will be widely disseminated through peer-reviewed publications, conference presentations and submitted to relevant authorities in national departments of health. Updates of the review will be conducted to inform and guide healthcare practice.

Acknowledgements: We acknowledge Dr Taryn Young, Evidence-based health care Centre, and University of Stellenbosch, who provided guidance for designing the protocol. Ms Tamzyn Sulieman, UCT Libraries, Health Sciences, Information Services Librarian provided, technical support and assisted in the planning of the search strategy and reference management. Finally, we gratefully

1
2
3 acknowledge support of the Evidence-Based Medicine Research Support Unit, Faculty of Health
4 Sciences at University of Cape Town.
5
6

7 **Contributors:** All authors conceived the study and were responsible for designing the protocol. M.
8 Werfalli and A Musekiwa co-drafted the protocol manuscript. ME Engel and NS Levitt provided
9 critical guidance on the analysis and overall direction of the study. I. Ross, A. Kengne revised it for
10 methodological and clinical content. All authors critically revised successive drafts of the manuscripts
11 and approved the final version.
12
13

14
15 **Funding:** None
16

17
18 **Competing interests:** None declared.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Guariguata L, Whiting D, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. *Diabetes Res Clin Pract* 2013;.
2. Alli F, Maharaj P. The Health Situation of Older People in Africa. *Aging and Health in Africa* Springer; 2013. p. 53-89.
3. Steyn K, Damasceno A. Lifestyle and related risk factors for chronic diseases. Disease and mortality in sub-Saharan Africa. 2006; 2.
4. Guariguata L, Whiting D, Weil C, et al. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. *Diabetes Res Clin Pract* 2011; 94(3):322-3
5. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart* 2008; 94(11):1376-82.
6. Naidoo N, Abdullah S, Bawah A, et al. Ageing and adult health status in eight lower-income countries: the INDEPTH WHO-SAGE collaboration. *Global Health Action* 2010:11
7. Sobngwi E, Mauvais-Jarvis F, Vexiau P, et al. Diabetes in Africans. *Diabetes Metab* 2001;27:628-34.
8. Dalal S, Beunza JJ, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: what we know now. *Int J Epidemiol* 2011; Aug; 40(4):885-901.
9. World Health Organization, World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. *Geneva: World Health Organization* 2006:1-50.
10. Eisinga A, Siegfried N, Clarke M. The sensitivity and precision of search terms in Phases I, II and III of the Cochrane Highly Sensitive Search Strategy for identifying reports of randomized trials in Medline in a specific area of health care—HIV/AIDS prevention and treatment interventions. *Health Information & Libraries Journal* 2007; 24(2):103-9.
11. Pienaar E, Grobler L, Busgeeth K, et al. Developing a geographic search filter to identify randomised controlled trials in Africa: finding the optimal balance between.
12. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 2012.
13. Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of interventions*. Wiley Online Library; 2008.

14. Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of interventions*. Wiley Online Library; 2008.

For peer review only

The tracked changes draft**The prevalence of type 2 diabetes mellitus among older people in Africa: A Systematic Review Study Protocol**

Correspondence to: [Naomi Levitt Naomi.levitt@uct.ac.za](mailto:Naomi.levitt@uct.ac.za) ~~Mahmoud Werfalli~~
Mahmoud.werfalli@yahoo.com

Mahmoud Werfalli^{1,4}, Alfred Musekiwa², Mark E Engel³, Ian Ross⁴, Andre P Kengne^{2,5} and Naomi S Levitt^{1,3,4}

Chronic Disease Initiative for Africa (CDIA),¹ Centre for Evidence Based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa² Department of Medicine, University of Cape Town, Cape Town, South Africa³, Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa⁴ Non-Communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, South Africa⁵

Key words: elderly, diabetes mellitus, type 2 diabetes, prevalence, Africa

Abstract

Introduction: The number of people with diabetes in Africa is projected to increase substantially in the next two decades, ~~due to explained by a number of factors including. These include~~ rapid urbanization, adoption of unhealthy diets and exercise patterns, and the ageing of the population. There are currently uncertainties regarding the incidence, prevalence, and management patterns of diabetes in older people across the diversity of African countries. We wish to perform a systematic review to determine the prevalence of type 2 diabetes in Africa in the older individual, over the age of 55 years, reported in studies from 2000 to 2013, ~~hypothesising that it may be higher than reported in Western countries.~~

Methods and analyses: A comprehensive literature search ~~among a number of databases~~ will be undertaken, using an African search filter to identify diabetes prevalence studies that were published from 2000 to 2013. ~~This specific e-African search filter comprises African country names as well as truncated terms such as 'north* Africa' to ensure that records indexed using regional terms rather than country-specific terms are also captured. Database subject headings (MeSH in PUBMED/MEDLINE, CINHALL, scholarly Google) will be combined with a range of text words (African search filter).~~

Publications of identified key authors will be examined by citation searches on MEDLINE and ISI Web of Science. The World Health Organization (WHO) and International Diabetes Federation (IDF) websites will be searched. Full copies of articles identified by the search, and considered to meet the inclusion criteria, will be obtained for data extraction and synthesis. Statistical analysis of the primary measures, fasting plasma glucose (FPG) and glucose tolerance test (OGTT) will include two steps: (1) identification of data sources and documenting estimates and (2), application of the random-effects meta-analysis model to aggregate prevalence estimates and account for between study variability in calculating the overall pooled estimates and 95% confidence interval (CI) for diabetes prevalence. Heterogeneity will be evaluated using the I-square statistic (I^2) to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. Two reviewers will apply the criteria independently to the results; prevalence of type 2 diabetes from different studies will be pooled in a meta-analysis using (STATA version 12 statistical software). This systematic review will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).

Formatted: Superscript

Ethics and dissemination: Ethics is not required for this study, given that this is a protocol for a systematic review, which utilizes published data. The findings of this study will be widely disseminated through peer-reviewed publications and conference presentations. Updates of the review will be conducted to inform and guide healthcare practice.

Introduction

During the last decade the prevalence of type 2 diabetes has increased dramatically in many parts of the world. The International Diabetes Federation (IDF) projects an increase in the number of people living with diabetes from 382 million in 2013 to 592 million by 2035, should there be no serious action to stem this tide.¹ In Africa, diabetes already contributes significantly to morbidity and mortality with the highest global age specific mortality rate recorded in this part of the world.²⁻⁵ As such a broad based strategy aimed at prevention, early identification and appropriate management is critical to reduce the burden of diabetes in Africa.⁵

The annual growth rate of older persons in Africa has been estimated at 3.1% between 2007 and 2015, and 3.3% between 2015 and 2050, which is greater than the global average.² Given that aging is one of the major drivers for diabetes, it is concerning that there will be approximately 64.5 million African persons aged ≥ 55 years in 2015, and more than 103 million and 205 million in 2030 and 2050, respectively.⁶ Delivering appropriate care for older people with diabetes presents a growing challenge to all health care systems. Health literacy, comorbidities, polypharmacy, higher risk of

Formatted: Font: Not Bold

cognitive impairment, functional limitations, and financial problems significantly affect the ability of older people in general to understand and follow complex treatment regimens.⁷ Yet guidelines for the older person with diabetes are limited by a dearth of evidence and therefore recommendations rely on expert opinion and extrapolation from younger populations.⁸ Diabetes, in view of its high prevalence, prolonged duration, wide spectrum of complications, emotional and psychological sequelae, provides a complex case for cost-effective studies, in older people.⁹

The most recent International Diabetes Federation estimates from 2013 are that 8.3% of adults *ie*, 382 million people world-wide have diabetes. This number has doubled over the past 20 years, and notably 80% of people with diabetes live in low and middle income countries (LMIC).¹

Diabetes already contributes significantly to morbidity and mortality in Africa. The highest global age-specific mortality rate is recorded in this continent.^{7-9, 2-6}

All countries in Africa fall all into the LMIC category, and predominantly the low income category. The rise in the number of people with **type 2** diabetes in Africa, similar to LMIC s been attributed to ageing of the population and relatively rapidly changing environmental factors.¹ These include urbanisation, the adoption of health behaviours favouring sedentariness and unhealthy eating patterns. While unhealthy behaviour patterns and obesity are potentially modifiable, ageing one of the major drivers for diabetes, is not.⁷ In 2013, the majority of individuals with diabetes in Africa were reported to be under than 60 years of age with the highest proportion (43.2%) in people aged 40–59 years.⁷ The relatively small proportion of people aged 60–79 years of age in the region is likely to account for the estimate that only 18.8% of people with diabetes fall in this age group.¹

Africa is often referred to as the youngest continent in terms of age structure. This may contribute to the current relatively low prioritisation of ageing issues in national policies.⁸ Yet the annual growth rate of older persons in Africa has been estimated at 3.1% between 2007 and 2015, and 3.3% between 2015 and 2050, greater than the global average. In this context, it is concerning that there will be approximately 64.5 million African persons aged ≥ 55 years in 2015, and more than 103 million and 205 million in 2030 and 2050, respectively.⁶ Indeed it has been predicted that the diabetes peak in Africa is expected to be in the oldest individual by 2035.¹

We therefore wish to perform a systematic review to determine the prevalence of type 2 diabetes in Africa in older individuals over the age of 55 years, reported in studies from 2000 to 2013 with a view to providing accurate data for monitoring future trends. The data will also be of value in informing health policy makers of the extent of the burden of diabetes in an under researched group whose health care needs may differ from those in younger adults.

- Formatted: Font color: Blue
- Formatted: Font color: Blue
- Formatted: Font: Bold, Font color: Blue
- Formatted: Font: Bold
- Formatted: Font color: Blue
- Formatted: Font color: Blue, Superscript
- Formatted: Font color: Blue
- Formatted: Space After: 0 pt, Line spacing: 1.5 lines, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers
- Formatted: Font color: Blue
- Formatted: Font: Bold, Font color: Blue
- Formatted: Font: Bold
- Formatted: Font color: Blue
- Formatted: Font color: Blue
- Formatted: Font: Not Bold, Font color: Blue
- Formatted: Font color: Blue
- Formatted: Line spacing: 1.5 lines
- Formatted: Font color: Blue
- Formatted: Font: Not Bold, Font color: Blue
- Formatted: Font color: Blue
- Formatted: Font: Not Bold, Font color: Blue, Not Superscript/ Subscript
- Formatted: Font color: Blue
- Formatted: Font color: Blue, English (U.S.)
- Formatted: Font color: Blue

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

|

For peer review only

Formatted: Justified, Space After: 0 pt, Line spacing: 1.5 lines, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers, Tab stops: Not at 3.76"

BMJ Open: first published as 10.1136/bmjopen-2013-004747 on 17 June 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Objectives

To conduct a systematic review and meta-analysis of studies assessing the prevalence of Type 2 diabetes among older people in African countries.

Review question

This systematic review will be guided by the following research question:

What is the prevalence of type 2 diabetes in older persons aged 55 years and older in African countries as reported in studies from 2000 to 2013?

Criteria for considering studies for review

~~We will consider published articles and unpublished studies reported after 01 January 2000, given that the current criteria for the diagnosis of diabetes have been widely accepted since 1998. Articles published in English or in other languages, with full English abstracts will be eligible for inclusion.~~

Inclusion criteria:

1. ~~Studies describing the prevalence of type 2 DM diabetes among older adults, resident in countries belonging to the African continent, in the geographic regions of both Sub-Saharan Africa and North Africa diagnosed with type 2 diabetes from all ethnicities, socioeconomic and educational backgrounds. Participants should be described as older adults or a minimum of 70% of participants should be under within these age groups age (of 55-64 years, 65-74 years, or and 75+ years).~~
2. ~~Population-based studies, cross-sectional studies of type 2 diabetes. For the purpose of this review, the diagnosis of diabetes should be made by ~~can either be made~~ by a physician or defined by available measured fasting plasma glucose (FPG), glucose tolerance test (OGTT) or self-reported, according to WHO criteria.⁹~~

~~We will consider published articles and unpublished studies reported after 01 January 2000, given that the current criteria for the diagnosis of diabetes have been widely accepted since 1998. Articles published in any language, with full English abstracts will be eligible for inclusion.~~

Exclusion criteria

1. ~~Studies which include a mixed group of Type 1 and Type 2 participants, or that do not clearly define the type of diabetes as being Type 2, will be excluded.~~

2. Studies confined to subgroups of patients with type 2 diabetes (with any complication of diabetes mellitus for example: myocardial infarction, eye, kidney or other microvascular or macrovascular complications).
3. Studies that do not include a representative sample of older people aged 55 years or older.
4. Narrative reviews, opinion pieces, letters, or any other publications lacking primary data and/or explicit methods descriptions.
5. Duplicate publications of the same material. When the study has been published in more than one journal/conference, the most complete recent version will be used.
6. They had a low quality scores (equal to or below 5) in the assessment of risk of bias.

Search strategy for identification of relevant studies

The search strategy will be designed to access both published and unpublished studies and will comprise two stages:

Bibliographic databases

- A. A comprehensive and sensitive search strategy will be undertaken using a comprehensive African search filter developed by Siegfried^{10 11} to identify prevalence studies conducted from 2000 to 2013 in Africa. The African filter comprises African country names from the continent as well as truncated terms such as 'north* Africa' to ensure that records indexed using regional terms rather than country-specific terms are also retrieved. Database subject headings (MeSH in PUBMED/MEDLINE, CINAHL and scholarly Google Scholar) will be combined with a range of text words (See Appendix 1). African country names are included in both English and languages relevant to the country, e.g., 'Ivory Coast' and 'Cote d'Ivoire'. Where country names have changed over time both names are included, e.g., 'Democratic Republic of Congo' and 'Zaire'.^{11,12}
- B. Publications of identified key authors will be examined by citation searches on the websites of the IDF and WHO websites e.g. STEPS surveys studies in Africa as well as 'free word' Internet searches on the ISI Web of Science of knowledge platform. No language restrictions will be used. A bibliographic software programmes for managing the references and documenting the study selection process (Ref Works) will be used in for this review. An expert librarian will help in designing the search strategy framework and implementing the appropriate bibliographic software program. (For the detailed search strategy, s (See Appendix 2).

Selecting studies for inclusion

Full copies of articles identified by the search, and considered to meet the inclusion criteria, based on the title and abstract will be obtained for data synthesis. Initially, studies will be screened using pre-defined inclusion and exclusion criteria. Two reviewers will apply the criteria independently to the results of the searches, based first on titles and abstracts only. Studies will then be either (A) excluded, (B) included, or (C) marked as "Pending" if the reviewer is unsure about their inclusion. The two independent reviews will be compared and contradictory judgments or "pending" will be temporarily "included", and moved to the next phase of review of full texts. Once full texts have been retrieved, two reviewers will independently apply inclusion and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

exclusion criteria, based on quick assessments of the full texts. Disagreements in reviewer selections will be resolved at a meeting between reviewers prior to selected articles being retrieved. A flow chart will be produced to facilitate transparency of the process.

Quality appraisal of included studies

A quality assessment tool, based on guidelines for evaluating prevalence studies as suggested by Hoy¹² and colleagues has been developed (Table 1). This ~~and~~ will be applied to screened full-text articles in order to code eligibility decisions and to assess study quality and agreement between investigators. Assessment of bias is built into the quality scoring scale. We plan to evaluate risk of selection and attrition bias using the Cochrane guidelines as set out in Review Manager version 5.2 (<http://ims.cochrane.org/RevMan>). This will inform the feasibility of and selection of studies for a pooled analysis. Any disagreements will be resolved by discussion and consensus in consultation with the third author to resolve persistent inconsistencies.

~~The strengths and limitations of systematic reviews and meta-analyses have been well established for randomized clinical trials, largely through the efforts of The Cochrane Collaboration. Although they have been used in parallel for observational epidemiological studies, such as cohort, case control and cross-sectional studies, considerably less attention has been paid to their methodology in this area of application. It is important, however, to distinguish between quality of reporting and quality of what was actually done in the design, conduct and analysis of a study. A high quality report ensures that all relevant information about a study is available to the reader, but does not necessarily reflect a low susceptibility to bias. An important component of a thorough systematic review is therefore an evaluation of the methodological quality of the primary research. For this purpose an innovative Guidelines for Evaluating Prevalence Studies have been developed by Hoy and other colleagues will be used in this review. They measure the quality of studies across two main areas: both external and internal validity (Table 1).~~

~~In this review, methodological quality will be distanced from general reporting quality as it is important to clarify and differentiate between quality of reporting and the quality of what was actually done (that is, a study could be well reported but have methodological limits or vice versa). Sensitivity analyses will be based on stratification, by individual items of methodological quality or (where appropriate) individual items of general reporting quality to assess the robustness of the findings. The Guidelines for Evaluating Prevalence Studies developed by Hoy¹³ will be used. These guidelines measure the quality of studies across two main areas: both external and internal validity (Table 1).~~

Table 1. Quality assessment criteria for Prevalence studies¹²⁴³

Items	Quality score
External validity	
1. Was the study's target population a close representation of the national population in relation to relevant variables?	(1 point)
2. Was the sampling frame a true or close representation of the target population?	(1 point)
3. Was some form of random selection used to select the sample, OR was a census undertaken?	(1 point)
4. Was the likelihood of nonresponse bias minimal?	(1 point)
	Total (4 points)
Internal validity	
1. Were data collected directly from the subjects (as opposed to a proxy)?	(1 point)
2. Was an acceptable case definition used in the study?	(1 point)
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability?	(1 point)
4. Was the same mode of data collection used for all subjects? (1 point)	(1 point)
5. Was the length of the shortest prevalence period for the parameter of interest appropriate?	(1 point)
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate?	(1 point)
	Total (6 points)

Data extraction and management

Following assessment of methodological quality, two reviewers will extract data onto a purpose-designed data extraction form and independently summarize what they consider to be the most important results from each study. These summaries will be compared and any differences of opinion will be resolved by discussion and consultation with a third reviewer. Any further calculations on study data considered necessary, will be conducted by the first reviewer and checked by the second reviewer. Study characteristics including country where study was conducted, year of publication, journal, language of publication, study population, age range, response rate, study design, criteria for sample selection and sample size, outcome(s) measured, diagnostic criteria, results and notes/comments will be presented in Tables (See Appendix 3). We are anticipating that some eligible studies will not have prevalence data reported for the specific age range (i.e. ≥ 55 years). We will contact the corresponding authors of these studies and request the age-specific prevalence and any other missing information, deemed to be relevant.

Data synthesis including assessment of heterogeneity

Our statistical analysis of the primary measures, FPG and OGTT will include two steps: (1) identification of data sources and documenting estimates and (2), application of the ~~a~~ random-effects meta-analysis model ~~—will be used to aggregate individual prevalence estimates and account for between study variability in calculating the overall pooled estimates and 95% confidence interval (CI) for diabetes prevalence. We will derive standard errors where studies have provided the corresponding numerator and denominator for diabetes prevalence estimates, the random effects method will be used to derive standard errors.~~ We will consider non overlapping CIs as an indication of statistically significant differences. Prevalence of type 2 DM from different studies will be pooled in a meta-analysis using (STATA version 12 statistical software). ~~Heterogeneity between combined studies will be tested using the I-square statistic (I²) heterogeneity statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. Heterogeneity will be assessed by inspecting forest plots initially, then through the Cochran's Chi-square test (using a 10% level of significance cut-off. due to the low power of the test), and the Heterogeneity between combined studies will be tested using the I-square statistic (I²) heterogeneity statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. I-square, where values of ~~(an I² (25%), I² (50%), and 75% reflected~~ low, medium, and high heterogeneity, respectively.¹³ Where heterogeneity is statistically significant, subgroup analysis, using the following variables: age group, sex, setting e.g. urban/ rural geographical region e.g., northern/ southern, Western/ Eastern, as well as ~~and~~ sensitivity analyses will be conducted to determine the potential sources of heterogeneity. ~~Subgroup analyses will be conducted by using the following variables age group, sex, setting e.g. urban/ rural geographical region e.g., northern/ southern, Western/ Eastern~~~~

Formatted: Font: (Default) Times New Roman

Furthermore a sensitivity analysis will be performed to evaluate how excluding studies that did not meet each quality criterion would affect our overall estimate. Another sensitivity analysis will be conducted to find out how our results would change if only high-quality studies were considered. If the identified studies are of substantial heterogeneity and where statistical pooling is not possible, the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. The narrative will be written by the two reviewers and then checked independently by the other reviewers, any disagreements will be decided by all reviewers.

Our analysis of the primary measure, FPG and OGTT will include two steps: (1) identification of data sources and documenting estimates and (2) application of statistical models, to estimate the prevalence by country and age. Prevalence of type 2 DM from different studies will be pooled in a meta-analysis using (STATA version 12 statistical software). Heterogeneity between combined studies will be tested using the I^2 heterogeneity statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. Heterogeneity will be assessed by inspecting forest plots initially, then through the Cochran's Chi square test (using 10% level of significance due to the low power of the test), and the I-square statistic (where 50% or higher values indicate substantial heterogeneity).¹⁴ Where heterogeneity is statistically significant, subgroup analysis and sensitivity analyses will be conducted to determine the potential sources of heterogeneity. If the identified studies are of substantial heterogeneity and where statistical pooling is not possible, the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. The narrative will be written by the two reviewers and then checked independently by the other reviewers, any disagreements will be decided by all reviewers.

Assessment of reporting biases

Symmetry of funnel plots will be used to assess for publication or selective reporting bias.

Reporting of this review

This systematic review will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement.^{14,15} A reporting guideline for systematic reviews of healthcare intervention and will include a PRISMA checklist. Where necessary, we will adapt the reporting to ensure that all items relevant to this review are included in the report.

Ethics and Dissemination

Given that this is a protocol for a systematic review, which utilizes published data, ethics is not required for this study. The findings of this study will be widely disseminated through peer-reviewed publications, conference presentations and submitted to relevant authorities in national departments of health. Updates of the review will be conducted to inform and guide healthcare practice.

~~This study will attempt to fill the gap in knowledge in the prevalence of diabetes among the older population in Africa. As such it will provide impetus to develop an evidence base for policy and practice in this area of research. The study will be disseminated by peer review publication and conference presentations.~~

Acknowledgements: We acknowledge Dr Taryn Young, Evidence-based health care Centre, and University of Stellenbosch, who provided guidance for designing the protocol. Ms Tamzyn Suliaman, UCT Libraries, Health Sciences, Information Services Librarian provided, technical support and assisted in the planning of the search strategy and reference management. Finally, we gratefully acknowledge support of the Evidence-Based Medicine Research Support Unit, Faculty of Health Sciences at University of Cape Town.

Contributors: All authors conceived the study and were responsible for designing the protocol. M. Werfalli and A Musekiwa co-drafted the protocol manuscript. ME Engel and NS Levitt provided critical guidance on the analysis and overall direction of the study. I. Ross, A. Kengne revised it for methodological and clinical content. All authors critically revised successive drafts of the manuscripts and approved the final version.

Funding: None

Competing interests: None declared.

References

1. [Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. *Diabetes Res Clin Pract* 2013;.](#)
2. [Alli F, Maharaj P. The Health Situation of Older People in Africa. *Aging and Health in Africa* Springer; 2013. p. 53-89.](#)
3. [Steyn K, Damasceno A. Lifestyle and related risk factors for chronic diseases. *Disease and mortality in sub-Saharan Africa*. 2006; 2.](#)
4. [Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. *Diabetes Res Clin Pract* 2011; 94\(3\):322-3](#)
5. [Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart* 2008; 94\(11\):1376-82.](#)
6. [Naidoo N, Abdullah S, Bawah A, Binka F, Chuc NT, Debpuur C, et al. Ageing and adult health status in eight lower-income countries: the INDEPTH WHO-SAGE collaboration. *Global Health Action* 2010;11](#)
7. [Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya J, Gautier J. Diabetes in Africans. *Diabetes Metab* 2001;27:628-34.](#)
8. [Dalal S, Beunza JJ, Volmink J, Adebamowo C, Bajunirwe F, Njelekela M, et al. Non-communicable diseases in sub-Saharan Africa: what we know now. *Int J Epidemiol* 2011; Aug; 40\(4\):885-901.](#)
9. [World Health Organization, World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. *Geneva: World Health Organization* 2006:1-50.](#)
10. [Eisinga A, Siegfried N, Clarke M. The sensitivity and precision of search terms in Phases I, II and III of the Cochrane Highly Sensitive Search Strategy for identifying reports of randomized trials in Medline in a specific area of health care—HIV/AIDS prevention and treatment interventions. *Health Information & Libraries Journal* 2007; 24\(2\):103-9.](#)
11. [Pienaar E, Grobler L, Busgeeth K, Eisinga A, Siegfried N. Developing a geographic search filter to identify randomised controlled trials in Africa: finding the optimal balance between.](#)
12. [Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 2012.](#)

Formatted: Font:

Formatted: Font: 11 pt

Formatted: Font: 11 pt

13. Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of interventions*. Wiley Online Library; 2008.

14. Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of interventions*. Wiley Online Library; 2008.

1- Leonor G. "Contribute data to the 6th edition of the IDF Diabetes Atlas." *Diabetes Res Clin Pract*. 100.2 (2013): 280-281.

2- Alli F, Maharaj P. *The Health Situation of Older People in Africa*. Aging and Health in Africa Springer; 2013. p. 53-89.

3- Steyn K, Damasceno A. Lifestyle and related risk factors for chronic diseases. *Disease and mortality in sub-Saharan Africa*. 2006; 2.

4- Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. *Diabetes Res Clin Pract* 2011; 94(3):322-3

5- Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart* 2008; 94(11):1376-82.

6- Naidoo N, Abdullah S, Bawah A, Binka F, Chue NT, Debpuur C, et al. Ageing and adult health status in eight lower income countries: the INDEPTH WHO SAGE collaboration. *Global Health Action* 2010:11

7- Sue Kirkman M, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. *J Am Geriatr Soc* 2012; 60(12):2342-56.

8- Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. *Oman Medical Journal* 2012; 27(4):269.

9- Varghese R. A clinical study of diabetes mellitus in elderly, with special emphasis on its complications 2012.

10- World Health Organization, World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. *Geneva: World Health Organization* 2006:1-50.

11- Eisinga A, Siegfried N, Clarke M. The sensitivity and precision of search terms in Phases I, II and III of the Cochrane Highly Sensitive Search Strategy for identifying reports of randomized trials in Medline in a specific area of health care—HIV/AIDS prevention and treatment interventions. *Health Information & Libraries Journal* 2007; 24(2):103-9.

12- Pienaar E, Grobler L, Busgeeth K, Eisinga A, Siegfried N. Developing a geographic search filter to identify randomised controlled trials in Africa: finding the optimal balance between sensitivity and precision. *Health Information & Libraries Journal* 2011; 28(3):210-5.

Formatted: List Paragraph, Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.55" + Indent at: 0.8"

Formatted: Font:

Formatted: Font: (Default) +Headings CS (Times New Roman)

Formatted: List Paragraph, Indent: Left: 0.8"

Formatted: Space Before: 0 pt, After: 0 pt, Don't add space between paragraphs of the same style

Formatted: Font: (Default) +Headings CS (Times New Roman)

Formatted: Normal, Space Before: Auto, After: Auto

Formatted: Indent: Left: 0.5", No bullets or numbering

1
2
3
4
5
6
7 13. ~~Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in~~
8 ~~prevalence studies: modification of an existing tool and evidence of interrater agreement. *J*~~
9 ~~*Clin Epidemiol* 2012.~~

10 14. ~~Higgins JP, Green S, Collaboration C. *Cochrane handbook for systematic reviews of*~~
11 ~~*interventions*. Wiley Online Library; 2008.~~

12 15. ~~Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic~~
13 ~~reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009; 151(4):264-9.~~

Formatted: Font: (Default) +Headings CS (Times New Roman)

Formatted: Normal, Indent: Left: 0.25", No bullets or numbering

For peer review only

Article summary

Article focus

- This systematic review aims to fill the gap in knowledge in the prevalence of diabetes among older population in Africa.

Key messages

- There are currently important gaps in our knowledge on the incidence and prevalence of diabetes mellitus and management patterns for older people in Africa, setting priorities in service delivery for the prevention and treatment of type 2 diabetes requires an empirical understanding of the pattern of disease burden

Strengths and limitations of this study

- A comprehensive search strategy will be undertaken using African search filter to identify prevalence Studies conducted from 2000 to 2013 in Africa.
- There is a lack of qualitative and quantitative research on the health status of the older population.
- Sensitivity analyses will be based on stratification by individual items of methodological quality.

Appendix 2: Describing details of search strategy

A. Describing the relevant search terms used in search strategy.

elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]
people	"persons"[MeSH Terms] OR "persons"[All Fields] OR "people"[All Fields]
diabetes mellitus	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields]
type 2 diabetes	"diabetes mellitus, type 2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]
Africa	"Africa"[MeSH Terms] OR "Africa"[All Fields]
diabetes	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR "diabetes"[All Fields] OR "diabetes insipidus"[MeSH Terms] OR ("diabetes"[All Fields] AND "insipidus"[All Fields]) OR "diabetes insipidus"[All Fields]
prevalence	"epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms]

B. Describing electronic databases searches by using of African Search Filter

(elderly)) AND (elderly people)) AND (diabetes mellitus)) AND (2 diabetes mellitus)) AND (type 2 diabetes)) AND (Africa)) AND (("Africa"[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR "Burkina Faso"[tw] OR Burundi[tw] OR Cameroon[tw] OR "Canary Islands"[tw] OR "Cape Verde"[tw] OR "Central African Republic"[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR "Democratic Republic of Congo"[tw] OR Djibouti[tw] OR Egypt[tw] OR "Equatorial Guinea"[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR "Guinea Bissau"[tw] OR "Ivory Coast"[tw] OR "Cote d'Ivoire"[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR "Sao Tome"[tw] OR Senegal[tw] OR Seychelles[tw] OR "Sierra Leone"[tw] OR Somalia[tw] OR "South Africa"[tw] OR "St Helena"[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR "Western Sahara"[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR "Central Africa"[tw] OR "Central African"[tw] OR "West Africa"[tw] OR "West African"[tw] OR "Western Africa"[tw] OR "Western African"[tw] OR "East Africa"[tw] OR "East African"[tw] OR "Eastern Africa"[tw] OR "Eastern African"[tw] OR "North Africa"[tw] OR "North African"[tw] OR "Northern Africa"[tw] OR "Northern African"[tw] OR "South African"[tw] OR "Southern Africa"[tw] OR "Southern African"[tw] OR "sub Saharan Africa"[tw] OR "sub Saharan African"[tw] OR "sub-Saharan Africa"[tw] OR "sub-Saharan African"[tw]) NOT ("guinea pig"[tw] OR "guinea pigs"[tw] OR 'aspergillums Niger'[tw])) AND (diabetes prevalence) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms])

APPENDIX 3: DATA EXTRACTION FORM

STUDY ID:

Reviewer's Initials

Part 1: COVERSHEET

Study Title:

Journal:

Language:

Citation:

Part 2: STUDY CHARACTERISTICS.

Publication Year:

Country of study:

<u>Study design:</u>	<u>Data source:</u>	<u>Setting</u>
<input type="checkbox"/> cross-sectional	<input type="checkbox"/> medical records	<input type="checkbox"/> Urban
<input type="checkbox"/> case-report	<input type="checkbox"/> special survey	<input type="checkbox"/> Rural
<input type="checkbox"/> other _____	<input type="checkbox"/> multiple source	
Study period: <input type="text"/>	<input type="checkbox"/> surveillance	
	<input type="checkbox"/> registries	
<u>Population study:</u>	<u>Age groups included (describe):</u>	
<input type="checkbox"/> total population	<input type="text"/>	
<input type="checkbox"/> specific group population	<u>Genders included:</u>	(Total numbers)
<input type="checkbox"/> other _____	Male <input type="checkbox"/>	<input type="text"/>
	Female <input type="checkbox"/>	<input type="text"/>
	Both <input type="checkbox"/>	<input type="text"/>
<u>Diagnostic Criteria.</u>	<u>Dominator (s) (N):</u>	
❖ WHO Criteria: (Y / N).	<input type="text"/>	
❖ Measured or Defined by:		
• Fasting plasma glucose (FPG) <input type="checkbox"/>		
• glucose tolerance test (OGT) <input type="checkbox"/>		
• Self-reported <input type="checkbox"/>		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>❖ Please use the attached checklist (Tick as appropriate (√))</p> <p>Inclusion criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Exclusion Criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Included <input type="checkbox"/> Excluded <input type="checkbox"/> pending <input type="checkbox"/></p>	<p>Reason(s) for exclusion, uncertainty or to contact authors</p> <div style="border: 1px solid black; padding: 5px; min-height: 60px;"> <p>1.</p> <p>2.</p> <p>3.</p> </div>
--	--

Part 3: RESULTS.

Measure of the prevalence

Crude Measure

Adjusted measure

If **adjusted** what factors were adjusted for in this study (list):

Reported measure of the prevalence:

Missing data to be reported from the author:
 (any communication with author Yes No
If yes, please specify

Other comments:

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1: African Search Filter

African Search Filter

(“Africa”[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR “Burkina Faso”[tw] OR Burundi[tw] OR Cameroon[tw] OR “Canary Islands”[tw] OR “Cape Verde”[tw] OR “Central African Republic”[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR “Democratic Republic of Congo”[tw] OR Djibouti[tw] OR Egypt[tw] OR “Equatorial Guinea”[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR “Guinea Bissau”[tw] OR “Ivory Coast”[tw] OR “Cote d’Ivoire”[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR “Sao Tome”[tw] OR Senegal[tw] OR Seychelles[tw] OR “Sierra Leone”[tw] OR Somalia[tw] OR “South Africa”[tw] OR “St Helena”[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR “Western Sahara”[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR “Central Africa”[tw] OR “Central African”[tw] OR “West Africa”[tw] OR “West African”[tw] OR “Western Africa”[tw] OR “Western African”[tw] OR “East Africa”[tw] OR “East African”[tw] OR “Eastern Africa”[tw] OR “Eastern African”[tw] OR “North Africa”[tw] OR “North African”[tw] OR “Northern Africa”[tw] OR “Northern African”[tw] OR “South African”[tw] OR “Southern Africa”[tw] OR “Southern African”[tw] OR “sub Saharan Africa”[tw] OR “sub Saharan African”[tw] OR “sub-Saharan Africa”[tw] OR “sub-Saharan African”[tw]) NOT (“guinea pig”[tw] OR “guinea pigs”[tw] OR ‘aspergillums Niger”[tw])

Appendix 2: Describing details of search strategy

A. Describing the relevant search terms used in search strategy.

elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]
people	"persons"[MeSH Terms] OR "persons"[All Fields] OR "people"[All Fields]
diabetes mellitus	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields]
type 2 diabetes	"diabetes mellitus, type 2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]
Africa	"Africa"[MeSH Terms] OR "Africa"[All Fields]
diabetes	"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR "diabetes"[All Fields] OR "diabetes insipidus"[MeSH Terms] OR ("diabetes"[All Fields] AND "insipidus"[All Fields]) OR "diabetes insipidus"[All Fields]
prevalence	"epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms]

B. Describing electronic databases searches by using of African Search Filter

(elderly)) AND (elderly people)) AND (diabetes mellitus)) AND (2 diabetes mellitus)) AND (type 2 diabetes)) AND (Africa)) AND (("Africa"[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR "Burkina Faso"[tw] OR Burundi[tw] OR Cameroon[tw] OR "Canary Islands"[tw] OR "Cape Verde"[tw] OR "Central African Republic"[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR "Democratic Republic of Congo"[tw] OR Djibouti[tw] OR Egypt[tw] OR "Equatorial Guinea"[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR "Guinea Bissau"[tw] OR "Ivory Coast"[tw] OR "Cote d'Ivoire"[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR "Sao Tome"[tw] OR Senegal[tw] OR Seychelles[tw] OR "Sierra Leone"[tw] OR Somalia[tw] OR "South Africa"[tw] OR "St Helena"[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR "Western Sahara"[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw] OR "Central Africa"[tw] OR "Central African"[tw] OR "West Africa"[tw] OR "West African"[tw] OR "Western Africa"[tw] OR "Western African"[tw] OR "East Africa"[tw] OR "East African"[tw] OR "Eastern Africa"[tw] OR "Eastern African"[tw] OR "North Africa"[tw] OR "North African"[tw] OR "Northern Africa"[tw] OR "Northern African"[tw] OR "South African"[tw] OR "Southern Africa"[tw] OR "Southern African"[tw] OR "sub Saharan Africa"[tw] OR "sub Saharan African"[tw] OR "sub-Saharan Africa"[tw] OR "sub-Saharan African"[tw]) NOT ("guinea pig"[tw] OR "guinea pigs"[tw] OR 'aspergillums Niger'[tw])) AND (diabetes prevalence) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms])

APPENDIX 3: DATA EXTRACTION FORM

STUDY ID:

Reviewer's Initials

Part 1: COVERSHEET

Study Title:

Journal:

Language:

Citation:

Part 2: STUDY CHARACTERISTICS.

Publication Year:

Country of study:

Study design:

- cross-sectional
- case-report
- other _____

Study period:

Population study:

- total population
- specific group population
- other _____

Diagnostic Criteria.

- ❖ WHO Criteria: (Y / N).
- ❖ Measured or Defined by:
 - Fasting plasma glucose (FPG)
 - glucose tolerance test (OGT)
 - Self-reported

Data source:

- medical records
- special survey
- multiple source
- surveillance
- registries

Setting

- Urban
- Rural

Age groups included (describe):

Genders included:

(Total numbers)

Male

Female

Both

Dominator (s) (N):

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>❖ Please use the attached checklist (Tick as appropriate (√))</p> <p>Inclusion criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Exclusion Criteria: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Included <input type="checkbox"/> Excluded <input type="checkbox"/> pending <input type="checkbox"/></p>	<p>Reason(s) for exclusion, uncertainty or to contact authors</p> <div style="border: 1px solid black; border-radius: 10px; padding: 10px; min-height: 80px;"> <p>1.</p> <p>2.</p> <p>3.</p> </div>
--	--

Part 3: RESULTS.

Measure of the prevalence

Crude Measure

Adjusted measure

If **adjusted** what factors were adjusted for in this study (list):


Reported measure of the prevalence:

Missing data to be reported from the author:
 (any communication with author Yes No
If yes, please specify

Other comments:



PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open: first published as 10.1136/bmjopen-2013-004747 on 17 June 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60